（一）出席会议情况 益丰大药房连锁股份有限公司 2024 年度独立董事履职报告（王小岩） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，2024 年本人严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董 事管理办法》《独立董事工作制度》等法律、法规以及《公司章程》的规定，恪 尽职守，勤勉尽责，充分发挥独立董事的独立作用，维护了公司及全体股东的利 益。现将 2024 年度本人履行独立董事职责的情况汇报如下： 一、 基本情况 （一）工作履历、专业背景及兼职情况 王小岩，男，中国国籍，无境外永久居留权，1976 年 2 月出生，工商管理 硕士，注册会计师、注册税务师、国际注册内部审计师。曾任德勤华永会计师事 务所高级审计员、广西丰林木业集团股份有限公司总裁助理、广西玉柴机器集团 有限公司审计总监、广州珠江云峰投资控股有限公司财务总监。现任蓝河乳业集 团有限公司财务总监。自 2024 年 6 月 26 日起，担任公司独立董事、审计委员会 召集人、提名委员会委员。 （二）履职独立性情况 作为公司独立董事，本人及本人的直系亲属、主要社会关系均不在公司或其 附属企业任职，不直接或间接有公司股份 ...

2024 年度独立董事履职报告（易兰广） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，本人任 职于 2024 年 6 月 25 日第四届董事会任期届满。任职期内，本人严格按照《公司 法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等法律法 规以及《公司章程》《独立董事工作制度》的规定，恪尽职守，勤勉尽责，充分 发挥独立董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人 履行独立董事职责的情况汇报如下： 一、 基本情况 （一）工作履历、专业背景及兼职情况 易兰广，男，中国国籍，无永久境外居留权，1976 年 12 月出生，管理科学 与工程博士，高级会计师职称。曾任三一重工有限公司子公司财务总监，国药控 股湖南有限公司副总经理、财务总监，九州通医药集团股份有限公司财务管理总 部部长。现任湖南泽华私募股权基金管理有限公司执行董事、总经理。2021 年 3 月 29 日至 2024 年 6 月 25 日期间，担任公司独立董事、审计委员会召集人、提 名委员会、薪酬与考核委员会委员。 （二）履职独立性情况 作为公司独立董事，本人及本人的直系亲属、主要社会关系均不在公司或其 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 6,009,043,521.27, representing a year-on-year increase of 0.64% compared to CNY 5,970,923,210.35 in the same period last year[4] - Net profit attributable to shareholders of the listed company reached CNY 449,493,528.80, marking a 10.51% increase from CNY 406,753,106.09 in the previous year[4] - Basic earnings per share rose to CNY 0.37, up 12.12% from CNY 0.33 in the previous year[4] - Net profit for Q1 2025 was ¥493,549,281.07, up 10.6% from ¥445,951,883.35 in Q1 2024[25] - Earnings per share (EPS) increased to ¥0.37 in Q1 2025 from ¥0.33 in Q1 2024, representing a growth of 12.1%[25] - The company reported an operating profit of ¥650,541,861.92, which is an increase from ¥593,522,472.65 in the previous year, reflecting a growth of 9.6%[24] Cash Flow - The net cash flow from operating activities significantly increased by 71.42%, amounting to CNY 1,114,385,691.58 compared to CNY 650,107,205.26 in the same period last year[4] - Cash inflow from operating activities totaled $6,700,021,854.84, an increase of 8.1% compared to $6,196,262,045.28 in the previous period[28] - The net cash flow from operating activities was $1,114,385,691.58, a significant increase from $650,107,205.26 in the prior period[28] - Total cash outflow for operating activities was $5,585,636,163.26, slightly up from $5,546,154,840.02 in the previous period[28] Assets and Liabilities - The total assets at the end of the reporting period were CNY 27,786,561,356.06, a decrease of 0.67% from CNY 27,974,736,950.35 at the end of the previous year[5] - The equity attributable to shareholders of the listed company increased by 4.28%, reaching CNY 11,185,232,095.24 compared to CNY 10,725,687,023.42 at the end of the previous year[5] - The company's total liabilities decreased to ¥15,893,358,192.95 from ¥16,581,173,472.42, a reduction of approximately 4.15%[20] - The total current liabilities decreased to RMB 12,103,474,750.82 from RMB 12,598,073,700.81, indicating a reduction of about 3.9%[19] - The company's long-term assets totaled RMB 11,911,046,281.79, down from RMB 12,118,954,736.84, reflecting a decrease of approximately 1.7%[19] Inventory and Receivables - The accounts receivable decreased to RMB 1,831,522,834.46 from RMB 2,123,984,911.43, showing a decline of approximately 13.8%[18] - Inventory levels decreased to RMB 4,371,628,158.53 from RMB 4,528,102,252.16, a reduction of about 3.5%[18] - The company accelerated the collection of accounts receivable, contributing to the significant increase in cash flow from operating activities[9] - The company reported a significant increase in other receivables, rising to RMB 556,953,713.36 from RMB 477,936,663.36, an increase of about 16.4%[18] Store Operations - The company opened 94 new stores in Q1 2025, including 26 self-built stores and 68 franchise stores, while closing 84 stores, resulting in a net increase of 10 stores, totaling 14,694 stores[14] Investment Income - The company reported an investment income of CNY 27,186,162.03, which is related to its daily operating activities[8] - The company’s investment income rose to ¥27,186,162.03 from ¥14,930,288.87, indicating an increase of approximately 81.5%[24] Other Financial Metrics - Non-recurring gains and losses for the period amounted to CNY 11,508,186.24 after tax and minority interests[7] - Other comprehensive income after tax for Q1 2025 was ¥9,609,750.00, a significant recovery from a loss of ¥44,204,850.00 in Q1 2024[25] - The weighted average return on net assets was 4.02%, slightly down from 4.06% in the previous year[5] - The company's cash and cash equivalents increased to RMB 3,964,045,471.35 from RMB 3,578,925,577.22, reflecting a growth of approximately 10.8%[18] - The company maintained a stable goodwill value of RMB 4,768,942,152.07, unchanged from the previous period[19]

益丰大药房连锁股份有限公司 2024 年度独立董事履职报告（颜爱民） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，本人 任职于 2024 年 6 月 25 日第四届董事会任期届满。任职期内，本人严格按照《公 司法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等法律法 规以及《公司章程》《独立董事工作制度》的规定，恪尽职守，勤勉尽责，充分 发挥独立董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人 履行独立董事职责的情况汇报如下： 一、 基本情况 （一）工作履历、专业背景及兼职情况 颜爱民，男，中国国籍，无永久境外居留权，1963 年 1 月出生，管理学博 士。中南大学商学院教授、博士生导师、中南大学人力资源研究中心（国家 CTTI 智库）主任/首席专家。曾任中南工业大学管理科学与工程系讲师、中南大学商 学院副教授，湖南千金药业股份有限公司独立董事、湖南黄金集团有限责任公司 外部董事。现任中南大学商学院二级教授、博士生导师、中南大学人力资源研究 中心（国家 CTTI 智库）主任/首席专家，上海肇民新材料科技股份有限公司 （301000）与湖南松井新材料股份有限公 ...

一、 基本情况 （一）工作履历、专业背景及兼职情况 益丰大药房连锁股份有限公司 2024 年度独立董事履职报告（王红霞） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，本人任 职于 2024 年 6 月 25 日第四届董事会任期届满。任职期内，本人严格按照《公司 法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等法律法 规以及《公司章程》《独立董事工作制度》的规定，恪尽职守，勤勉尽责，充分 发挥独立董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人 履行独立董事职责的情况汇报如下： 王红霞，女，中国国籍，无永久境外居留权，1979 年 7 月出生，博士后学 历，律师职称。现任中南大学副教授、博士生导师。2021 年 3 月 29 日至 2024 年 6 月 25 日期间，担任公司独立董事、提名委员会召集人、审计委员会委员。 （二）履职独立性情况 作为公司独立董事，本人及本人的直系亲属、主要社会关系均不在公司或其 附属企业任职，不直接或间接持有公司股份，不在直接或间接持有公司已发行股 份 5%及以上或公司前五名股东单位任职，不在公司控股股东、实际控制人的附 属企业 ...

益丰大药房连锁股份有限公司 2024 年度独立董事履职报告（秦拯） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，2024 年本人严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董 事管理办法》《独立董事工作制度》等法律、法规以及《公司章程》的规定，恪 尽职守，勤勉尽责，充分发挥独立董事的独立作用，维护了公司及全体股东的利 益。现将 2024 年度本人履行独立董事职责的情况汇报如下： 一、 基本情况 （一）工作履历、专业背景及兼职情况 秦拯，男，中国国籍，无境外永久居留权，1969 年出生，工学博士、管理 学博士后，湖南大学教授、博士生导师，湖南大学大数据处理与行业应用研究中 心主任、大数据研究与应用湖南省重点实验室主任，教育部网络空间安全教指委 委员、中国工程教育专业认证专家，中国计算机学会大数据专委会委员，中国人 工智能学会智能服务专委会委员、人工智能与安全专委会委员，湖南制造强省建 设专家咨询委员会委员、湖南省网络安全与信息化专家咨询委员会委员。现任湖 南梦洁股份有限公司（002397）、拓维信息系统股份有限公司（002261）独立董 事。自 2024 年 6 月 26 日 ...

Investment Rating - The industry investment rating is "Outperform" [2] Core Viewpoints - Recent developments from Johnson & Johnson regarding PFA products indicate that domestic PFA brands are expected to enter a commercialization fast track in 2025, with significant growth potential in the market [5][6][17] - The medical biology sector has shown a weekly increase of 1.16%, outperforming the CSI 300 index by 0.77 percentage points, with the medical research outsourcing sector experiencing the highest growth of 6.34% [18][21] Summary by Sections Weekly Insights - Johnson & Johnson presented three key PFA products at the HRS2025 conference, showcasing their safety, effectiveness, and usability [14][15] - The domestic PFA market is projected to reach 1.3 billion yuan in 2025 and exceed 16.3 billion yuan by 2032, with a compound annual growth rate of 43.73% [17] Sector Performance - The medical research outsourcing sector had the highest weekly increase of 6.34%, while the vaccine sector saw the largest decline of 3.78% [7][21] - The report highlights a significant divergence in performance across sub-sectors, with the medical biology sector ranking 15th among 31 sub-industries [18][24] Recommended and Benefiting Stocks - Recommended stocks include Microelectrophysiology, Maipu Medical, and Yingke Medical [8] - Benefiting stocks include Huatai Medical, Weili Medical, and BGI Genomics [8][30] Market Trends - The report notes that the medical device sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI integration in medical imaging and surgical applications [25][29] - The IVD sector is anticipated to see growth driven by AI-assisted diagnostics and favorable government policies [29] Specific Sector Analysis - The blood products sector is facing challenges due to high inventory levels and competitive pressures, but long-term demand for albumin remains stable [32] - The offline pharmacy sector is undergoing consolidation, with leading pharmacies expected to benefit from increased customer traffic and improved profit margins [33][34]

益丰药房（603939）公告，2024年度实现归属于母公司净利润15.29亿元，同比增长8.26%。公司拟向全 体股东每股派发现金红利0.4元(含税)，合计拟派发现金红利4.85亿元(含税)。 ...

Core Viewpoint - The China Securities Index for the medical industry has shown a decline in performance over various time frames, indicating potential challenges within the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry has decreased by 5.99% over the past month, 1.12% over the past three months, and 6.26% year-to-date [2]. - The index was established with a base date of December 31, 2021, set at 1000.0 points [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.15%) - Aier Eye Hospital (9.35%) - United Imaging (8.03%) - Aimeike (4.1%) - Huatai Medical (3.87%) - New Industry (3.16%) - Shanghai Pharmaceuticals (3.11%) - Yuyue Medical (3.06%) - Yifeng Pharmacy (2.49%) - Meinian Onehealth (2.45%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (56.76%) and the Shanghai Stock Exchange (43.24%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.77% - Medical Consumables: 22.92% - Pharmaceutical Commerce: 15.73% - Medical Services: 14.44% - In Vitro Diagnostics: 12.14% [2]. Group 4: Sample Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].